TERAPIJA PACIJENATA SA FILADELFIJA HROMOZOM POZITIVNOM HRONIČNOM
MIJELOIDNOM LEUKEMIJOM IMATINIB MESILATOM Page 1 16 Autori: Ivana Vidanović1 …

Imatinib Mesylate is an inhibitor of tyrosine kinase activity of chimeric BCR-ABL gene,
situated at chromosome 22, and has been considered as a “targeted therapy” in the …

The new knowledge in molecular biology and pathophysiology of chronic myeloid leukemia
enabled the development of imatinib mesylate (Glivec, formerly STI571). Imatinib potently …

2) Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl
tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.3) Druker …

The International Randomized Study of Interferon and STI571 (IRIS) study prospectively
compared imatinib with interferon-alpha/low-dose cytarabine (IFN/LDAC) in 1,106 newly …

Metode Analizirana su 22 odrasla bolesnika sa novodijagnostikovanom Filadelfija-
pozitivnom ranom hroničnom fazom HML, lečena u našoj ustanovi od juna 2006. do …

The Efficacy and Tolerability of Generic of Imatinib in a Very Specific Group of Chronic Myeloid
Leukemia - ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books …

Imatinib mesylate is a relatively new drug that targets the BCR-ABL chimeric protein, the
molecular basis of chronic myeloid leukemia (CML). A phase II clinical trial in 39 Japanese …

Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the
development and progression of Philadelphia chromosome–positive (Ph+) chronic …

Summary Abstract Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor used
in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the …